CMLF SEC filings, in plain English
Everything CM Life Sciences, Inc. has filed with the SEC that we hold — 40 filings, newest first, 4 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: 8-K of GeneDx Holdings Corp. Item 2.02 (results of operations and financial condition): on August 3, 2026 the Company issued a press release and will hold a conference call announcing its financial results for the quarter ended June 30, 2026. The press release and an earnings presentation are furnished as Exhibits 99.1 and 99.2. The information furnished with Item 2.02, including both exhibits, shall not be deemed filed for Section 18 purposes nor incorporated by reference. Signed by CEO Katherine Stueland. Why it matters: Routine quarterly earnings furnishing; the report states no figure. Item 9.01 lists no cover-page Inline XBRL exhibit, unlike the other earnings 8-Ks filed the same week.
What changed: The successor to CM Life Sciences, Inc. filed its Q2 2026 10-Q reporting cash, cash equivalents and available-for-sale marketable securities of $132.5 million at June 30, 2026, which it says gives at least twelve months of liquidity. Class A shares outstanding rose to 29,803,164 from 29,245,296 at December 31, 2025 and total liabilities to $237.3 million from $215.5 million. Operating activities used $61.4 million of cash in the six months, driven by a net loss of $81.1 million. Contingent consideration of up to $10.5 million is payable if Fabric Genomics reaches $6.0 million of gross revenue. Why it matters: Routine quarterly reporting for a completed de-SPAC — no trust, redemption right or deadline remains. The number that matters is runway: $132.5 million on hand against $61.4 million of operating cash burn in six months is roughly a year of cover on the current rate, which is why management flags possible future sales of common or preferred equity or convertible debt. Any of those routes dilutes the 29.8 million shares outstanding, and the Fabric Genomics earnout adds up to $10.5 million payable in cash or stock on top.
What changed: Item 5.07: GeneDx Holdings Corp held its annual meeting on June 18, 2026, with 29,675,547 Class A shares outstanding on the April 20, 2026 record date. Stockholders elected one Class II director to a three-year term expiring in 2029, ratified Ernst & Young as independent registered public accounting firm for the fiscal year ending December 31, 2026 by 27,466,639 for and 158,884 against, approved executive compensation on an advisory basis by 22,705,946 for and 1,471,593 against, and voted for annual say-on-pay frequency with 23,816,121 votes for one year. Why it matters: This is a routine annual meeting for a company that came public via a SPAC, and every proposal passed. The one substantive data point is the say-on-pay vote: 1,471,593 against out of roughly 24.2 million votes cast on that proposal is about 6% opposition, which is modest but higher than the near-unanimous auditor ratification, and shareholders chose annual rather than triennial future votes. No financial results, transactions or capital changes are disclosed.
What changed: GeneDx Holdings Corp., successor to CM Life Sciences, Inc., called a virtual annual meeting for June 18, 2026 at 9:00 a.m. ET, record date April 20, 2026, with materials distributed on or about April 30, 2026. The compensation discussion reports full-year 2025 results: exome and genome test revenue grew 54% year over year to $360.3 million, or 58% excluding a one-time 2024 benefit; adjusted gross margin expanded to 71% from 65% in 2024; and adjusted net income reached $41.8 million against $9.4 million for full year 2024. The company states it achieved its 2025 performance target goals. Why it matters: Revenue growth of 54% to $360.3 million with adjusted net income more than quadrupling to $41.8 million puts GeneDx in the small minority of de-SPAC successors operating profitably on an adjusted basis. For holders that removes the financing overhang that dominates this cohort - the company is not dependent on issuing stock to fund the next year, and the 71% adjusted gross margin gives operating leverage room as volumes grow.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.